ADTX Stock Summary and Trading Ideas (Aditxt | NASDAQ:ADTX)

Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.

Aditxt trades on the NASDAQ stock market under the symbol ADTX.

As of March 27, 2023, ADTX stock price climbed to $0.89 with 6,646 million shares trading.

ADTX has a beta of 3.46, meaning it tends to be more sensitive to market movements. ADTX has a correlation of 0.26 to the broad based SPY ETF.

ADTX has a market cap of $3.82 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that ADTX belongs to (by Net Assets): VXF.

ADTX has underperformed the market in the last year with a price return of -96.6% while the SPY ETF lost -10.7%. ADTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.2% and -16.4%, respectively, while the SPY returned +3.7% and +2.9%, respectively.

ADTX support price is $.81 and resistance is $.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADTX stock will trade within this expected range on the day.